banner https://www.profitablecpmrate.com/nsirjwzb79?key=c706907e420c1171a8852e02ab2e6ea4

Novo chairman to step down in board rift over pace of change

Novo Nordisk A/S Chairman Helge Lund is stepping down after a boardroom dispute over the pace of change and will be replaced by Lars Rebien Sorensen, a previous leader of the Danish drugmaker who now heads its biggest shareholder. The move is part of a wider shakeup at the maker of Wegovy and Ozempic drugs, … Read more

Novo Nordisk board members step down after major shareholder dispute

The logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy is seen outside theri building as the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025. Mads Claus Rasmussen | Afp | Getty Images Several Novo Nordisk board members will step … Read more

Novo Nordisk flags Wegovy pill weight loss in line with injection

Flags with the logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy are pictures while the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025.  Mads Claus Rasmussen | Afp | Getty Images Novo Nordisk said Wednesday that late-stage trial results … Read more

Novo Nordisk flags Cagrilintide promise in hunt for next obesity drug

The logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy is seen outside theri building as the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025. Mads Claus Rasmussen | Afp | Getty Images Novo Nordisk on Wednesday flagged promising late-stage … Read more

Obesity pills from Eli Lilly, Novo Nordisk near US launch

Eli Lilly and Novo Nordisk are preparing to take their rivalry to the next frontier of weight-loss medications: pills. Both companies expect to launch oral obesity drugs in the U.S. next year, once regulators approve them. Daily pills could introduce more people to GLP-1s, the class of medicine that’s best known for weekly shots. But … Read more

Wegovy-maker Novo Nordisk to cut around 9,000 jobs

Wegovy injection pens arranged in Waterbury, Vermont, US, on Monday, April 28, 2025. Shelby Knowles | Bloomberg | Getty Images Danish pharmaceutical giant Novo Nordisk on Wednesday announced plans to cut around 9,000 roles, or roughly 11.5% of its global workforce. “Novo Nordisk today announced a company-wide transformation to simplify its organisation, improve the speed … Read more

Wegovy trial result gives boost to Novo Nordisk amid U.S. market woes

A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Hollie Adams | Reuters New trial data suggests Novo Nordisk’s weight loss drug Wegovy edges out rival treatments on heart condition risk reduction, in good news for the Danish pharma giant as it … Read more

Denmark slashes 2025 growth forecast amid Novo Nordisk slowdown

The logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy is seen outside theri building as the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025. Mads Claus Rasmussen | Afp | Getty Images Denmark on Friday slashed its annual growth … Read more

Eli Lilly’s obesity pill will rival Novo Nordisk’s oral Wegovy drug

A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly‘s stock is still recovering after the drugmaker released trial data earlier this month on its closely watched obesity pill that underwhelmed Wall Street. In a key late-stage trial, … Read more

Novo Nordisk offers diabetes drug Ozempic for steep cash discount

A box of Ozempic made by Novo Nordisk, at a pharmacy in London on March 8, 2024. Hollie Adams | Reuters Novo Nordisk on Monday said it now offers cash-paying U.S. patients its blockbuster diabetes treatment Ozempic for less than half its monthly list price, as drugmakers face mounting political pressure to lower prices in … Read more

banner banner https://www.profitablecpmrate.com/nsirjwzb79?key=c706907e420c1171a8852e02ab2e6ea4